183 related articles for article (PubMed ID: 37934325)
1. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325
[TBL] [Abstract][Full Text] [Related]
2. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
Schnoell J; Stanisz I; Jank BJ; Stanek V; Schmid R; Brunner M; Heiduschka G; Kotowski U
Invest New Drugs; 2022 Apr; 40(2):224-231. PubMed ID: 34613571
[TBL] [Abstract][Full Text] [Related]
3. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
[TBL] [Abstract][Full Text] [Related]
5. VE-822 Enhanced Cisplatin Chemotherapy Effects on Head and Neck Squamous Cell Carcinoma Drug-resistant Cells.
Chen T; Yang F; Dai X; Yu Y; Sun Y; Wu X; Li R; Zhou Q
Curr Cancer Drug Targets; 2023; 23(6):482-495. PubMed ID: 36748213
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma.
Karukonda P; Odhiambo D; Mowery YM
Mol Carcinog; 2022 Feb; 61(2):225-238. PubMed ID: 34964992
[TBL] [Abstract][Full Text] [Related]
7. The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines.
Haas M; Lenz T; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2022 Aug; 40(4):700-708. PubMed ID: 35412173
[TBL] [Abstract][Full Text] [Related]
8. Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts.
Yao W; Qian X; Ochsenreither S; Soldano F; DeLeo AB; Sudhoff H; Oppel F; Kuppig A; Klinghammer K; Kaufmann AM; Albers AE
Cells; 2021 Feb; 10(3):. PubMed ID: 33671083
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
Roy S; Roy S; Kar M; Chakraborty A; Kumar A; Delogu F; Asthana S; Hande MP; Banerjee B
Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct; 846():503084. PubMed ID: 31585633
[TBL] [Abstract][Full Text] [Related]
10. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Shapiro GI; Wesolowski R; Devoe C; Lord S; Pollard J; Hendriks BS; Falk M; Diaz-Padilla I; Plummer R; Yap TA
Br J Cancer; 2021 Aug; 125(4):520-527. PubMed ID: 34040174
[TBL] [Abstract][Full Text] [Related]
12. The cGAS/STING/IFN-1 Response in Squamous Head and Neck Cancer Cells after Genotoxic Challenges and Abrogation of the ATR-Chk1 and Fanconi Anemia Axis.
Zahnreich S; El Guerzyfy S; Kaufmann J; Schmidberger H
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834346
[TBL] [Abstract][Full Text] [Related]
13. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
[TBL] [Abstract][Full Text] [Related]
14. HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines.
Foki E; Stanisz I; Kadletz L; Kotowski U; Seemann R; Schmid R; Heiduschka G
Wien Klin Wochenschr; 2021 Jan; 133(1-2):26-31. PubMed ID: 32876741
[TBL] [Abstract][Full Text] [Related]
15. Combination Treatment of Withalongolide a Triacetate with Cisplatin Induces Apoptosis by Targeting Translational Initiation, Migration, and Epithelial to Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.
Subramanian C; Spielbauer KK; Pearce R; Kovatch KJ; Prince ME; Timmermann BN; Cohen MS
Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558560
[TBL] [Abstract][Full Text] [Related]
16. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
17. Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro.
Jank BJ; Lenz T; Haas M; Kadletz-Wanke L; Campion NJ; Schnoell J; Heiduschka G; Macfelda K
Invest New Drugs; 2022 Jun; 40(3):478-486. PubMed ID: 34985593
[TBL] [Abstract][Full Text] [Related]
18. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
19. Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers.
Dok R; Glorieux M; Bamps M; Nuyts S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546122
[TBL] [Abstract][Full Text] [Related]
20. Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells.
Dobler C; Jost T; Hecht M; Fietkau R; Distel L
Cells; 2020 Sep; 9(9):. PubMed ID: 32883016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]